other material
confidence high
sentiment positive
materiality 0.65
Palvella announces QTORIN pitavastatin for DSAP; Phase 2 trial planned H2 2026
PALVELLA THERAPEUTICS, INC.
- New candidate targets DSAP, a rare genetic skin disease with no FDA-approved therapies.
- DSAP affects an estimated >50,000 diagnosed U.S. patients and is premalignant.
- Company plans to meet FDA in H1 2026; Phase 2 trial initiation expected H2 2026.
- QTORIN pitavastatin designed to inhibit the mevalonate pathway, the causal driver of DSAP.